Global pharmaceutical markets experienced another stabilization in Potassium Clavulanate prices this month, following March&#xx;s downward trend. The key beta-lactamase inhibitor, crucial in fighting antibiotic resistance, continues its price correction for the second month running at major trading centers in China, USA, and Germany.
Potassium Clavulanate prices fell by x.xx in Chinese export markets since mid-April, after falling x.xxx in March with the prices at USD xxxxxx/MT FOB Shanghai. This consistent correction is a much-needed relief to drug makers who use Potassium Clavulanate in combination antibiotics.
The market for Potassium Clavulanate is being characterized by abnormal stability relative to other active pharmaceutical ingredients, since pricing strategies have been actively being realigned by suppliers to manage seasonal demand patterns and avoid stockpile accumulation
Large drug manufacturers in the USA and Germany, which are major importers, stand to gain substantially from such price correction. The stabilization in prices...
